Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • IDT Australia can now manufacture medicinal hemp products to Good Manufacturing Practice (GMP) standards
  • It has a leading position in the medical hemp industry as Boronia manufacturing campus is vertically integrated
  • the company received its own Medicinal Cannabis Manufacturing License from the Department of Health

IDT Australia can now manufacture medicinal hemp products to Good Manufacturing Practice (GMP) standards.

In May the company received its own Medicinal Cannabis Manufacturing License from the Department of Health – Office Drug Control.

Along with the active pharmaceutical ingredient and finished dosage form, Therapeutic Goods Administration and the Poisons Licenses and Victorian Department of Health and Human Services, the company is working towards a fully licensed GMP manufacturing assets.

A GMP is required for the manufacturing of active pharmaceutical ingredients (API) and finished dosages (capsules, tablets), for this case for medicinal hemp products.

IDT is a science and technology company that develops pharmaceutical products.

API is the key chemicals that make the drug work.

“On the global stage, GMP manufacturing standards are also becoming increasingly more important as the hemp industry expands from lesser regulated international markets like Canada to more regulated markets like Germany,” the company said.

IDT manufacturing capabilities will include solid forms (liquid bottle, capsules, gel caps, tablets), respiratory or nasal spray, dermal (creams, ointments, patches) and liquid fill products.

It has a leading position in the medical hemp industry as Boronia manufacturing campus is vertically integrated, meaning it is capable of producing API’s and finished dosage forms.

CEO Dr David Sparling said the company is now fully licensed for medical hemp.

“IDT is now fully licensed for medicinal hemp operations, the site is vertically integrated in terms of GMP API and finished dosage form manufacture, and IDT has decades of history of working with botanically derived pharmaceutical products,” he said.

The company has a long history in GMP manufacture of Both API’s and Finished Dosage Forms.

“IDT will continue to leverage these key differentiators; and believe that IDT is well placed to further expand its footprint as a centre of excellence in GMP medicinal cannabis manufacturing on the global stage,” David added.

IDT by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.